The FDA on December 20, 2017 granted regular approval to the anti-PD1 monoclonal antibody OPDIVO® for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. OPDIVO® was previously approved for the treatment of patients with unresectable or metastatic melanoma. OPDIVO® is a product of Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
